Page 4 Cost effectiveness of telehealth for patients with long term conditions WSD telehealth study
P. 4
BMJ 2013;346:f2065 doi: 10.1136/bmj.f2065 (Published 28 March 2013) Page 4 of 6
CORRECTIONS
Table 5| [CORRECTED VERSION] Differences in costs* and effect between treatment groups at 12 month follow-up, from net benefit
analyses. Data are mean (95% confidence interval) unless otherwise stated
Between group difference
Usual care (n=431) Telehealth (n=534) or ICER (95% CI)
Primary outcome
QALY (raw mean difference)† 0.549 (0.52 to 0.577) 0.560 (0.535 to 0.585) 0.012 (−0.026 to 0.049)
Cost (£; raw mean difference)† 5559 (4752 to 6366) 6384 (5688 to 7081) 826 (−689 to 2340)
QALY (adjusted mean difference)§‡ — — 0.012
Cost (£; adjusted mean difference)§ 5401 (4498 to 6305) 6511 (5905 to 7116) 1110 (−1 to 2220)
ICER (£ per QALY)§¶ — — 92 000 (0 to undefined)
Costs excluding project management costs (£)
Raw mean difference† 5555 (4748 to 6362) 6193 (5491 to 6895) 637 (−427 to 1702)
Adjusted mean difference§ 5395 (4492 to 6297) 6322 (5712 to 6933) 928 (−184 to 2040)
ICER (£ per QALY)§¶ — — 79 000 (undefined)
Sensitivity analyses
Equipment prices reduced by 50%
Cost (£; adjusted mean difference)§ 5395 (4492 to 6298) 6174 (5566 to 6782) 779 (−333 to 1890)
ICER (£ per QALY)§¶ — — 68 000 (undefined)
Equipment prices reduced by 80%
Cost (£; adjusted mean difference)§ 5391 (4488 to 6295) 5972 (5362 to 6582) 580 (−532 to 1693)
ICER (£ per QALY)§¶ — — 52 000 (undefined)
Operating at increased capacity
Cost (£; adjusted mean difference)§ 5395 (4491 to 6299) 6034 (5430 to 6638) 639 (−471 to 1749)
ICER (£ per QALY)§¶ — — 57 000 (undefined)
Operating at increased capacity and equipment prices reduced by 50%
Cost (£; adjusted mean difference)§ 5389 (4486 to 6293) 5697 (5090 to 6304) 308 (−803 to 1419)
ICER (£ per QALY)§¶ — — 31 000 (undefined)
Operating at increased capacity and equipment prices reduced by 80%
Cost (£; adjusted mean difference)§ 5386 (4482 to 6289) 5495 (4886 to 6104) 109 (−1002 to 1221)
ICER (£ per QALY)§¶ — — 12 000 (undefined)
Secondary outcomes
ICECAP-O
Raw mean difference† 0.751 (0.734 to 0.768) 0.766 (0.75 to 0.781) 0.014 (−0.011 to 0.031)
Adjusted mean difference§‡ — — 0.012
ICER (£)§¶ — — 98 000 (8000 to undefined)
Brief STAI
Raw mean difference† 11.495 (11.093 to 11.896) 10.694 (10.347 to 11.04) −0.801 (−1.327 to −0.275)
Adjusted mean difference§‡** — — −0.762
ICER (£)§¶ — — 27 000 (1000 to 86 000)
CESD-10
Raw mean difference† 10.506 (9.882 to 11.13) 9.725 (9.17 to 10.281) −0.781 (−1.613 to 0.052)
Adjusted mean difference§‡†† — — −0.639
ICER (£)§¶ — — 9000 (0 to 160 000)
£1=€1.14; $1.49.
*Annual equivalent costs.
†Cases for which costs data at baseline were available.
‡Derived from slope of net monetary benefit line.
§From net benefit analyses, data adjusted for baseline costs, baseline outcome, site, demographic covariates (age, sex, ethnicity, IMD, number of chronic conditions,
index condition).
¶Rounded to nearest 1000.
**Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.042.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
CORRECTIONS
Table 5| [CORRECTED VERSION] Differences in costs* and effect between treatment groups at 12 month follow-up, from net benefit
analyses. Data are mean (95% confidence interval) unless otherwise stated
Between group difference
Usual care (n=431) Telehealth (n=534) or ICER (95% CI)
Primary outcome
QALY (raw mean difference)† 0.549 (0.52 to 0.577) 0.560 (0.535 to 0.585) 0.012 (−0.026 to 0.049)
Cost (£; raw mean difference)† 5559 (4752 to 6366) 6384 (5688 to 7081) 826 (−689 to 2340)
QALY (adjusted mean difference)§‡ — — 0.012
Cost (£; adjusted mean difference)§ 5401 (4498 to 6305) 6511 (5905 to 7116) 1110 (−1 to 2220)
ICER (£ per QALY)§¶ — — 92 000 (0 to undefined)
Costs excluding project management costs (£)
Raw mean difference† 5555 (4748 to 6362) 6193 (5491 to 6895) 637 (−427 to 1702)
Adjusted mean difference§ 5395 (4492 to 6297) 6322 (5712 to 6933) 928 (−184 to 2040)
ICER (£ per QALY)§¶ — — 79 000 (undefined)
Sensitivity analyses
Equipment prices reduced by 50%
Cost (£; adjusted mean difference)§ 5395 (4492 to 6298) 6174 (5566 to 6782) 779 (−333 to 1890)
ICER (£ per QALY)§¶ — — 68 000 (undefined)
Equipment prices reduced by 80%
Cost (£; adjusted mean difference)§ 5391 (4488 to 6295) 5972 (5362 to 6582) 580 (−532 to 1693)
ICER (£ per QALY)§¶ — — 52 000 (undefined)
Operating at increased capacity
Cost (£; adjusted mean difference)§ 5395 (4491 to 6299) 6034 (5430 to 6638) 639 (−471 to 1749)
ICER (£ per QALY)§¶ — — 57 000 (undefined)
Operating at increased capacity and equipment prices reduced by 50%
Cost (£; adjusted mean difference)§ 5389 (4486 to 6293) 5697 (5090 to 6304) 308 (−803 to 1419)
ICER (£ per QALY)§¶ — — 31 000 (undefined)
Operating at increased capacity and equipment prices reduced by 80%
Cost (£; adjusted mean difference)§ 5386 (4482 to 6289) 5495 (4886 to 6104) 109 (−1002 to 1221)
ICER (£ per QALY)§¶ — — 12 000 (undefined)
Secondary outcomes
ICECAP-O
Raw mean difference† 0.751 (0.734 to 0.768) 0.766 (0.75 to 0.781) 0.014 (−0.011 to 0.031)
Adjusted mean difference§‡ — — 0.012
ICER (£)§¶ — — 98 000 (8000 to undefined)
Brief STAI
Raw mean difference† 11.495 (11.093 to 11.896) 10.694 (10.347 to 11.04) −0.801 (−1.327 to −0.275)
Adjusted mean difference§‡** — — −0.762
ICER (£)§¶ — — 27 000 (1000 to 86 000)
CESD-10
Raw mean difference† 10.506 (9.882 to 11.13) 9.725 (9.17 to 10.281) −0.781 (−1.613 to 0.052)
Adjusted mean difference§‡†† — — −0.639
ICER (£)§¶ — — 9000 (0 to 160 000)
£1=€1.14; $1.49.
*Annual equivalent costs.
†Cases for which costs data at baseline were available.
‡Derived from slope of net monetary benefit line.
§From net benefit analyses, data adjusted for baseline costs, baseline outcome, site, demographic covariates (age, sex, ethnicity, IMD, number of chronic conditions,
index condition).
¶Rounded to nearest 1000.
**Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.042.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
